Clinical Leukemia最新文献_第2页

New Insights into the Molecular Pathogenesis of Bcr-Abl–Negative Myeloproliferative Disorders bcr - abl阴性骨髓增生性疾病分子发病机制的新认识

Clinical Leukemia Pub Date : 2009-02-01 Epub Date: 2013-02-21 DOI: 10.3816/CLK.2009.n.004

Isabelle Plo , Ronan Chaligné , Chloé James , William Vainchenker

引用次数: 0

The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia 造血干细胞移植在成人急性髓性白血病中的作用

Clinical Leukemia Pub Date : 2009-02-01 Epub Date: 2013-02-21 DOI: 10.3816/CLK.2009.n.006

Mehdi Hamadani , William Blum

{"title":"The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia","authors":"Mehdi Hamadani , William Blum","doi":"10.3816/CLK.2009.n.006","DOIUrl":"https://doi.org/10.3816/CLK.2009.n.006","url":null,"abstract":"<div><p>Advances in understanding of the molecular basis of acute myeloid leukemia (AML) are finally beginning to allow tailoring of therapy for patients based on relapse risk. Although remission-induction therapy for most patients today remains predominantly “one-fits-all” cytarabine-based chemotherapy, postremission treatments are becoming more individualized based on cytogenetic or molecular markers of disease. Successive cooperative group trials over the past decade have helped to clarify a role for allogeneic hematopoietic stem cell transplantation (HSCT) for patients with AML in first remission based on cytogenetic risk stratification. More recently, molecular risk stratification has also been helpful in identifying patients who benefit from early transplantation. Herein, we review the current state of allogeneic and autologous HSCT in AML, discuss the role for transplantation in patients with normal-karyotype leukemia, and provide practical recommendations for postremission strategies for AML in first complete remission. We also discuss the role for HSCT in advanced AML, for patients lacking suitable donors, and in older adults with reduced-intensity conditioning.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"3 1","pages":"Pages 47-57"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2009.n.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights from the 2008 Meeting of the American Society of Hematology San Francisco, CA; December 6–9, 2008 2008年美国血液学会旧金山会议要点;2008年12月6日至9日

Clinical Leukemia Pub Date : 2009-02-01 Epub Date: 2013-02-21 DOI: 10.3816/CLK.2009.n.001

Marissa Shrader PhD, Bing-e Xu PhD, Jorge E. Cortés MD, Stefan Faderl MD

引用次数: 0

MicroRNAs: The jack of all trades microrna:万事通

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.003

S. Rehman, G. Baldassarre, G. Calin, M. Nicoloso

引用次数: 2

Telomere Biology in T Cells: An Important Brake on the Road of Their Life Span? T细胞的端粒生物学:它们寿命之路上的一个重要刹车?

Clinical Leukemia Pub Date : 2009-02-01 Epub Date: 2013-02-21 DOI: 10.3816/CLK.2009.n.005

Alexander Röth , Gabriela M. Baerlocher

引用次数: 0

Central nervous system relapse in acute promyelocytic leukemia: Two cases and a systematic review 急性早幼粒细胞白血病的中枢神经系统复发:2例及系统回顾

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.007

M. Tomblyn, K. Dusenbery, M. Tomblyn

{"title":"Central nervous system relapse in acute promyelocytic leukemia: Two cases and a systematic review","authors":"M. Tomblyn, K. Dusenbery, M. Tomblyn","doi":"10.3816/CLK.2009.N.007","DOIUrl":"https://doi.org/10.3816/CLK.2009.N.007","url":null,"abstract":"Abstract Central nervous system (CNS) relapse in patients with acute promyelocytic leukemia (APL) is an uncommon event but increasingly reported in the all-trans-retinoic acid (ATRA) era. No standard of care for treating these patients currently exists. We describe 2 cases and review previous reports. Review of the medical literature revealed 61 additional patients, ranging in age from 3.5 to 73 years (median, 39 years). Leukocyte count at initial diagnosis ranged from 1.3 to 307 × 109/L (median, 25.6 × 109/L). Nearly all received ATRA first-line. Only 36% of the relapses were isolated to the CNS, and 86% of patients suffered from neurologic symptoms. Patients were treated with intrathecal chemotherapy alone, radiation alone, or both. In total, 75% of patients treated achieved CNS remission. The success rate of achieving CNS remission by combining radiation and intrathecal chemotherapy was 100%, superior to either modality alone (50% and 75%, respectively). All patients treated with craniospinal radiation were alive and free of disease at 1 year. Patients with APL should be fully evaluated at onset of new neurologic symptoms. Patients with APL with CNS relapse warrant systemic workup because most will not have isolated disease.","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"1 1","pages":"58-64"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87466014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Central Nervous System Relapse in Acute Promyelocytic Leukemia: Two Cases and a Systematic Review 急性早幼粒细胞白血病的中枢神经系统复发:2例及系统回顾

Clinical Leukemia Pub Date : 2009-02-01 Epub Date: 2013-02-21 DOI: 10.3816/CLK.2009.n.007

Michael B. Tomblyn , Kathryn E. Dusenbery , Marcie R. Tomblyn

{"title":"Central Nervous System Relapse in Acute Promyelocytic Leukemia: Two Cases and a Systematic Review","authors":"Michael B. Tomblyn , Kathryn E. Dusenbery , Marcie R. Tomblyn","doi":"10.3816/CLK.2009.n.007","DOIUrl":"https://doi.org/10.3816/CLK.2009.n.007","url":null,"abstract":"<div><p>Central nervous system (CNS) relapse in patients with acute promyelocytic leukemia (APL) is an uncommon event but increasingly reported in the all-<em>trans</em>-retinoic acid (ATRA) era. No standard of care for treating these patients currently exists. We describe 2 cases and review previous reports. Review of the medical literature revealed 61 additional patients, ranging in age from 3.5 to 73 years (median, 39 years). Leukocyte count at initial diagnosis ranged from 1.3 to 307 × 10<sup>9</sup>/L (median, 25.6 × 10<sup>9</sup>/L). Nearly all received ATRA first-line. Only 36% of the relapses were isolated to the CNS, and 86% of patients suffered from neurologic symptoms. Patients were treated with intrathecal chemotherapy alone, radiation alone, or both. In total, 75% of patients treated achieved CNS remission. The success rate of achieving CNS remission by combining radiation and intrathecal chemotherapy was 100%, superior to either modality alone (50% and 75%, respectively). All patients treated with craniospinal radiation were alive and free of disease at 1 year. Patients with APL should be fully evaluated at onset of new neurologic symptoms. Patients with APL with CNS relapse warrant systemic workup because most will not have isolated disease.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"3 1","pages":"Pages 58-64"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2009.n.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia 急性髓系白血病临床试验的入组标准

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.002

G. Schiller, M. Sekeres

{"title":"Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia","authors":"G. Schiller, M. Sekeres","doi":"10.3816/CLK.2009.N.002","DOIUrl":"https://doi.org/10.3816/CLK.2009.N.002","url":null,"abstract":"Abstract Emerging diagnostic and therapeutic developments give insight into the heterogeneous disease biology of acute myeloid leukemia (AML) and provide valuable prognostic information regarding response to therapies and targets for investigational treatments. Our understanding of AML has evolved from morphologic and cytochemical distinctions to cytogenetics-based classification systems. The most recent evolutionary step has been the recognition of the prognostic importance of pathobiologic variations, such as in FLT3 , NPM, and c-Kit; and of clinical disease features, particularly age, de novo versus secondary disease, and remission status. Therapies designed to reverse or inhibit the mechanisms that appear to cooperate in the AML pathobiologic pathway have been developed, including those that target Bcl-2, Ras, hypermethylation, heat shock protein, multidrug resistance efflux pumps, tyrosine kinase activation, histone deacetylation, and FLT3 . Despite this progress, clinical features still serve as the platform for entry into clinical trials of novel agents. As the driving mechanisms of leukemia pathogenesis become further defined, and the inhibition of said mechanisms at a molecular level are correlated to clinical response, future studies should enroll patients on the basis of these molecular features, perhaps in isolation of clinical features, as variables such as age and secondary disease are intermediate markers for underlying pathobiology.","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"13 1","pages":"14-19"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84131016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Anagrelide on JAK2 Mutational Status in Patients with Essential Thrombocythemia 阿那格列特对原发性血小板增多症患者JAK2突变状态的影响

Clinical Leukemia Pub Date : 2008-11-01 Epub Date: 2013-02-21 DOI: 10.3816/CLK.2008.n.038

Emma Cacciola, Ernesto Di Francesco, Francesca Pezzella, Daniele Tibullo, Rossella Cacciola

引用次数: 4

Type B Core Binding Factor β/Smooth Muscle Myosin Heavy Chain Fusion Transcript in Myeloid Blast Phase of Chronic Myeloid Leukemia: Correlation with Nuclear and Cytoplasmic Localization of the Fusion Protein B型核心结合因子β/平滑肌肌球蛋白重链融合转录物在慢性髓性白血病髓母细胞期:与融合蛋白的核和细胞质定位的相关性

Clinical Leukemia Pub Date : 2008-11-01 Epub Date: 2013-02-21 DOI: 10.3816/CLK.2008.n.035

C. Cameron Yin , Dan Jones , Jorge E. Cortés , Hagop Kantarjian , Mihai Merzianu , L. Jeffrey Medeiros , Carlos E. Bueso-Ramos

{"title":"Type B Core Binding Factor β/Smooth Muscle Myosin Heavy Chain Fusion Transcript in Myeloid Blast Phase of Chronic Myeloid Leukemia: Correlation with Nuclear and Cytoplasmic Localization of the Fusion Protein","authors":"C. Cameron Yin , Dan Jones , Jorge E. Cortés , Hagop Kantarjian , Mihai Merzianu , L. Jeffrey Medeiros , Carlos E. Bueso-Ramos","doi":"10.3816/CLK.2008.n.035","DOIUrl":"10.3816/CLK.2008.n.035","url":null,"abstract":"<div><h3>Background</h3><p>Inv(16)(p13q22) or the rare t(16;16)(p13;q22) is characteristic of the M4Eo type of acute myeloid leukemia and results in the fusion of the core binding factor β gene <em>(CBFB)</em> at 16q22 with the smooth muscle myosin heavy chain gene <em>(MYH11)</em> at 16p13. The fusion transcript <em>CBFB/MYH11</em> plays an important role in leukemogenesis. Many variations of this fusion transcript have been reported, with type A being most common and occurring in > 85% of cases.</p></div><div><h3>Patients and Methods</h3><p>We studied the fusion transcripts in 4 cases of chronic myelogenous leukemia in myeloid blast phase with inv(16)(p13q22).</p></div><div><h3>Results</h3><p>Sequencing analysis revealed type B fusion transcript in 3 of the 4 cases. Immunohistochemistry demonstrated both nuclear and cytoplasmic staining for the fusion protein.</p></div><div><h3>Conclusion</h3><p>Although the biologic significance of this finding is unknown, the high frequency of an unusual type of fusion transcript in the chronic myelogenous leukemia cases in blast phase in which inv(16)(p13q22) first occurred at the time of blast transformation suggests that the type B transcript might play a role in disease progression. The effect of the additional smooth muscle myosin heavy chain sequences in the type B fusion on subcellular localization of the protein product is also suggested.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"2 4","pages":"Pages 257-260"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2008.n.035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88336819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3